Pharmaceutical Executive
Think of the role compliance plays in your job. Now imagine that level of concern increased by 25 percent, 50, or even more. That's what pharma has to look forward to in the next few years, as the effects of old regulatory initiatives, such as 21 CFR Part 11 and Sarbanes Oxley, start fully kicking in-and as we experience the as-yet-unknown regulatory fallout of the new concern with drug safety. It's no surprise that a great portion of this volume of Pharm Exec's Successful Product Manager's Handbook series is given over to compliance.
Think of the role compliance plays in your job. Now imagine that level of concern increased by 25 percent, 50, or even more. That's what pharma has to look forward to in the next few years, as the effects of old regulatory initiatives, such as 21 CFR Part 11 and Sarbanes Oxley, start fully kicking in—and as we experience the as-yet-unknown regulatory fallout of the new concern with drug safety. It's no surprise that a great portion of this volume of Pharm Exec's Successful Product Manager's Handbook series is given over to compliance.
Patrick Clinton
The team at Polaris Management explains how to make compliance part of company culture. A company with compliance in its DNA has a better chance of anticipating change, rather than just reacting to it.
An issue that should be on everyone's radar is sampling, argues Steve Tarnoff of the Franklin Group. Devoting most of its promotional budget to sampling, industry passed out twice the dollar amount in samples as it did five years ago. Who could object? OIG for one.
Kashif Chaudry and Anne Love of Clarescent discuss ways companies might use sales force automation and other tools to bridge communication gaps among internal groups, and manage relationships with key opinion leaders. Without communication, doctors are being paid three, four, even five times by the same source for consulting in different areas—and the company doesn't even know it.
Finally, Christopher Lisanti and Pat Pesanello of BusinessEdge Solutions asked 100 high-potential primary-care physicians their greatest frustrations with pharma sales reps. That's something everyone in pharma needs to know. Do you?
Patrick Clinton is Pharmaceutical Executive's editor-in-chief and can be reached at pclinton@advanstar.com
FDA Grants Priority Review to AstraZeneca’s Calquence for Previously Untreated Mantle Cell Lymphoma
October 3rd 2024Priority Review was based on data from the ECHO Phase III trial, which demonstrated that a combination of Calquence, bendamustine, and rituximab reduced the risk of disease progression or death by 27% in patients with previously untreated mantle cell lymphoma.
FDA Approves Fresenius Kabi, Formycon’s Stelara Biosimilar for Multiple Inflammatory Diseases
October 2nd 2024Marketed as a biosimilar to Stelara, approval of Otulfi was based on clinical data demonstrating comparable efficacy in treating inflammatory conditions such as Crohn disease, ulcerative colitis, moderate to severe plaque psoriasis, and active psoriatic arthritis.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.